IXICO has completed a fundraising
March 2026 — IXICO plc, a specialist in AI-driven neuroimaging analytics, has completed a gross capital raise of US$13.5 million. The funds will be used to support the company’s tech bio strategy, enabling IXICO to partner its platform more broadly and maximize its potential.
IXICO plc is a precision neuroscience company. Its AI-enabled neuroimaging platform supports clinical trials for neurological diseases, including Alzheimer’s and Huntington’s disease, helping biopharmaceutical companies make better and faster decisions in drug development.
Our role in the transaction
Oaklins Cavendish, one of Oaklins’ member firms in the UK, acted as the sole bookrunner and broker for IXICO plc’s US$13.5 million capital raise.
Talk to the deal team
Related deals
Mattina Holding has sold a 5% stake in Gens Aurea via accelerated bookbuild
Mattina Holding S.A. (DVC Partners) has sold a 5% stake in Italian company Gens Aurea S.p.A. through an accelerated bookbuild, raising approximately US$69.96 million.
Learn moreVeremark has completed a secondary share sale
Veremark, the global workplace trust company, has completed an employee and early investor secondary share sale, on the London Stock Exchange’s (LSE) Private Securities Market (PSM), valuing the company at over US$133 million in enterprise value. Crowdcube, Europe’s leading private market liquidity platform, managed the transaction.
Learn moreKatalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
Learn more